Effect of co-administration of voglibose and vildagliptin on diabetic albino rats

Umashanker PD Keshri, Mukesh Kumar, Bhulan PD Loc, Manju Gari, Janardan Sharma, Rajiv Kumar


Background: The progressive nature of type 2 diabetes usually requires a combination of two or more oral agents in long term. Studies have been done to support its relevance. This study was made to observe the possible additive or supra-additive effect of the co-administration of voglibose and vildagliptin expecting it to be beneficial by enhancing the peptide GLP-1 activity which in turn increases insulin secretion while decreasing that of glucagon in response to rise in plasma glucose.

Methods: Healthy male wistar rats weighing 150-250 grams were taken for this study. The animals were divided into five groups, six animals in each group. These groups were normal control, diabetic control, vildagliptin treated, voglibose treated and by vildagliptin and voglibose (co-administered) treated group diabetic rats. Diabetes was induced by freshly prepared nicotinamide followed by streptozotocin intraperitoneal injection. The fasting blood samples were determined by glucose oxidase method. One way ANOVA test was used to compare the effect of drugs on different group.

Results: Fasting blood glucose in normal control was found static. Diabetic rats fasting blood glucose level subsequently increased in different weeks. The animal treated by vildagliptin and voglibose orally has a better control of FBS in comparison to diabetic control group. The animal treated by co-administration of vildagliptin and voglibose had a better effect than vildagliptin treated group and voglibose treated animal.

Conclusions: Vildagliptin and voglibose are effective in lowering blood glucose level in albino diabetic rats but their combination has potentiating effect.


Voglibose, Vildagliptin, Nicotinamide, Streptozotocin

Full Text:



Gobal prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetic Care. 2004;27(5):1047-53.

Laurence LB, Bruce AC, Bjorn KC. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In: Goodman and Gillman’s Pharmacological Basis of Therapeutics: Alpha glucosidase inhibitor. 2012;43:1264-65.

Winker G. Incretin enhancers, incretin mimetics from therapeutic-control to clinical application. Ory Hetil. 2007;148:579-87.

Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanism of action. Diabetes Care. 2007;30:1335-43.

Yamaguchi M, Saji T, Mita S, Kulmatycki K, He YL, Furihata K, et al. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with type 2 diabetes. Int J Clin Pharmacol Ther. 2013;51(8):6414-5.

He H, Tran P, Yin H. Absorption, metabolism, and excretion of (14C) vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos. 2009;37:536-44.

Ghosh MN. Toxicity studies. In: Ghosh MN, editor, Fundamentals of Experimental Pharmacology 5th ed, Kolkata: Hilton and Company; 2011:167.

Nayak Y, Hillemane V, Daroji VK, Jayashree BS, Unnikrishnan MK. Antidiabetic activity of benzopyrone analogues in nicotinamide-streptozotocin induced type 2 diabetes in rats. The Scientific World Journal Volume. 2014;2014:854267.

Gandhi GR, Sasikumar P. Antidiabetic effect of merremia emarginata burm F. in streptozotocin induced diabetic rats. Asian Pac J Trop Biomed. 2012;2(4):281-6.

Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Buys DH, et al. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes. 1998;47:224-9.

Moritoh Y, Takeuchi K, Hazama M. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J Pharmacol Exp Ther. 2009;329(2):669-76.

Ahren B, Landin-Olsson M, Jansson P. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:2078-84.

Mari A, Sallas M, He YL, Watson C, Ligueros-Saylan M, Dunning BE, et al. Vildagliptin, a dipeptidyl peptidase IV inhibitor, improves model-assessed ß-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:4888-94.

He YL, Sadler BM, Sabo R, Balez S, Wang Y, Campestrini J, et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidyl peptidase IV inhibitor, vildagliptin, in healthy volunteers. Clinical Pharmacokinetics. 2007;46:787-802.

Sunkara G, Sabo R, Wang Y, He YL, Campestrini J, Rosenberg M, et al. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clinical Pharmacology. 2007;47:1152-8.

Katoaka Y, Yasuda S, Miyamota Y, Sase K, Kosuge M, Kimura K, et al. Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early stage diabetic patients.Circulation Journal. 2012;76(3):712-20.

Goke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, Littke T, et al. Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion. 1995(6);56:493-501.